{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:28:23Z","timestamp":1784302103720,"version":"3.55.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100019085","name":"Japanese Respiratory Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019085","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015778","name":"Kanagawa Prefectural Hospital Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015778","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008728","name":"Japan Research Foundation for Clinical Pharmacology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008728","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019085","name":"Japanese Respiratory Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019085","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019085","name":"Kanagawa Prefectural Hospital Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019085","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019085","name":"Japan Research Foundation for Clinical Pharmacology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019085","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>A fatal acute exacerbation (AE) occasionally develops during chemotherapy for small cell lung cancer (SCLC) with comorbid idiopathic pulmonary fibrosis (IPF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to assess the safety and efficacy of carboplatin, etoposide, and nintedanib combination therapy for unresectable SCLC with comorbid IPF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The NEXT-SHIP study is a multicenter, single-arm, phase 2 trial for unresectable SCLC with IPF (Japan Registry of Clinical Trials registry number jRCTs031190119). The patients received carboplatin, etoposide, and nintedanib (150\u2009mg twice daily). The primary endpoint was the incidence of IPF-AE at 28\u2009days after the last administration of cytotoxic chemotherapy, and the sample size was set at 33 (5.0% expected, 20.0% threshold).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 33 patients were registered; 87.9% were male, the median age was 73\u2009years, the median percentage forced vital capacity was 85.2%, and 51.5% had honeycomb lungs. The median observation period was 10.5 months. The incidence of IPF-AE at 28\u2009days after the last administration of cytotoxic chemotherapy was 3.0% (90% confidence interval [CI], 0.2\u201313.6). The objective response rate was 68.8% (95% CI, 50.0\u201383.9). The median progression-free survival and overall survival times were 4.2 months (95% CI, 4.2\u20135.5) and 13.4 months (95% CI, 8.1\u201321.6), respectively. The most common adverse event of grade 3 or higher was neutropenia (81.8%), followed by leukopenia (39.4%) and thrombocytopenia (30.3%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study met its primary endpoint regarding the incidence of IPF-AEs with promising results for efficacy. Carboplatin, etoposide, and nintedanib combination therapy may be one of the standard treatment options for SCLC with comorbid IPF.<\/jats:p>\n                    <jats:p>Clinical trial registered with the Japan Registry of Clinical Trials (jRCTs031190119).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202311-941oc","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T16:07:25Z","timestamp":1708099645000},"page":"635-643","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":13,"title":["Nintedanib Plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis"],"prefix":"10.1093","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5203-7911","authenticated-orcid":false,"given":"Satoshi","family":"Ikeda","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terufumi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Kenmotsu","sequence":"additional","affiliation":[{"name":"Division of Thoracic Oncology, Shizuoka Cancer Center, Sunto-gun, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Agemi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and"},{"name":"Department of Medical Oncology, Yokohama Municipal Citizen\u2019s Hospital, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Tokito","sequence":"additional","affiliation":[{"name":"Division of Respirology Neurology and Rheumatology, Department of Internal Medicine, Kurume University Hospital, Kurume, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Matsusaka Municipal Hospital, Matsusaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohsuke","family":"Isomoto","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kindai University Hospital, Osakasayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Takiguchi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Chiba University Hospital, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuto","family":"Yoneshima","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihide","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japan Community Health Care Organization Hokkaido Hospital, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Tanzawa","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Itabashi-ku, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae","family":"Iwasawa","sequence":"additional","affiliation":[{"name":"Department of Radiology, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Misumi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and"},{"name":"Department of Medical Oncology, Yokohama Municipal Citizen\u2019s Hospital, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,1]]},"reference":[{"issue":"Suppl 2","key":"2026012203145573100_bib1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1038\/sj.bjc.6602061","article-title":"The epidemiology of interstitial lung disease and its association with lung cancer","volume":"91","author":"Raghu","year":"2004","journal-title":"Br J Cancer"},{"key":"2026012203145573100_bib2","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.lungcan.2013.08.024","article-title":"Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis","volume":"82","author":"Yamaguchi","year":"2013","journal-title":"Lung Cancer"},{"key":"2026012203145573100_bib3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/JTO.0000000000000359","article-title":"Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer","volume":"10","author":"Ueki","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2026012203145573100_bib4","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.resinv.2019.06.001","article-title":"Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia","volume":"57","author":"Ogura","year":"2019","journal-title":"Respir Investig"},{"key":"2026012203145573100_bib5","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.3390\/cancers13163979","article-title":"Current treatment strategies for non-small-cell lung cancer with comorbid interstitial pneumonia","volume":"13","author":"Ikeda","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026012203145573100_bib6","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/JTO.0b013e318216ee6b","article-title":"The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer","volume":"6","author":"Kenmotsu","year":"2011","journal-title":"J Thorac Oncol"},{"key":"2026012203145573100_bib7","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/JTO.0b013e3182103d3c","article-title":"The feasibility study of carboplatin plus etoposide for advanced small cell lung cancer with idiopathic interstitial pneumonias","volume":"6","author":"Minegishi","year":"2011","journal-title":"J Thorac Oncol"},{"key":"2026012203145573100_bib8","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s10147-013-0554-5","article-title":"Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis","volume":"19","author":"Watanabe","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"2026012203145573100_bib9","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1080\/17476348.2016.1249854","article-title":"Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis","volume":"10","author":"Fukihara","year":"2016","journal-title":"Expert Rev Respir Med"},{"key":"2026012203145573100_bib10","doi-asserted-by":"crossref","first-page":"1900161","DOI":"10.1183\/13993003.00161-2019","article-title":"Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases","volume":"54","author":"Wollin","year":"2019","journal-title":"Eur Respir J"},{"key":"2026012203145573100_bib11","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40265-021-01487-0","article-title":"Nintedanib: a review in fibrotic interstitial lung diseases","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"2026012203145573100_bib12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomized controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol"},{"key":"2026012203145573100_bib13","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012203145573100_bib14","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012203145573100_bib15","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012203145573100_bib16","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203145573100_bib17","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/thoraxjnl-2014-206598","article-title":"The INPULSIS enigma: exacerbations in idiopathic pulmonary fibrosis","volume":"70","author":"Suissa","year":"2015","journal-title":"Thorax"},{"key":"2026012203145573100_bib18","doi-asserted-by":"crossref","first-page":"1758835920923431","DOI":"10.1177\/1758835920923431","article-title":"Rationale and protocol design for the TORG1835\/NEXT-SHIP study: a phase II study of carboplatin, etoposide and nintedanib for unresectable limited\/extensive disease small cell lung cancer with idiopathic pulmonary fibrosis","volume":"12","author":"Ikeda","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"11 suppl","key":"2026012203145573100_bib19","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1016\/j.jtho.2023.09.249","article-title":"MA18.08 A phase 2 study of carboplatin, etoposide and nintedanib for unresectable small-cell lung cancer with idiopathic pulmonary fibrosis [abstract]","volume":"18","author":"Agemi","year":"2023","journal-title":"J Thorac Oncol"},{"key":"2026012203145573100_bib20","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203145573100_bib21","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.rmed.2014.04.011","article-title":"Design of the INPULSIS\u2122 trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis","volume":"108","author":"Richeldi","year":"2014","journal-title":"Respir Med"},{"key":"2026012203145573100_bib22","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1164\/rccm.200703-463PP","article-title":"Acute exacerbations of idiopathic pulmonary fibrosis","volume":"176","author":"Collard","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203145573100_bib23","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012203145573100_bib24","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026012203145573100_bib25","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"2026012203145573100_bib26","doi-asserted-by":"crossref","first-page":"100408","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"key":"2026012203145573100_bib27","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00262-020-02539-2","article-title":"Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancer","volume":"69","author":"Shibaki","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"2026012203145573100_bib28","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1111\/cas.15117","article-title":"Real-world safety of nivolumab in patients with non-small-cell lung cancer in Japan: postmarketing surveillance","volume":"112","author":"Yamamoto","year":"2021","journal-title":"Cancer Sci"},{"key":"2026012203145573100_bib29","doi-asserted-by":"crossref","first-page":"e2022906","DOI":"10.1001\/jamanetworkopen.2020.22906","article-title":"Association of preexisting interstitial lung abnormalities with immune checkpoint inhibitor-induced interstitial lung disease among patients with nonlung cancers","volume":"3","author":"Shimoji","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026012203145573100_bib30","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jtho.2020.08.018","article-title":"A phase 2 study of atezolizumab for pretreated NSCLC with idiopathic interstitial pneumonitis","volume":"15","author":"Ikeda","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2026012203145573100_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.06.008","article-title":"A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia","volume":"111","author":"Fujimoto","year":"2017","journal-title":"Lung Cancer"},{"key":"2026012203145573100_bib32","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.lungcan.2019.06.001","article-title":"Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: a multicenter, open-label single-arm phase II trial","volume":"134","author":"Fujimoto","year":"2019","journal-title":"Lung Cancer"},{"key":"2026012203145573100_bib33","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1111\/cas.14217","article-title":"Phase II study of nab-paclitaxel + carboplatin for patients with non-small-cell lung cancer and interstitial lung disease","volume":"110","author":"Kenmotsu","year":"2019","journal-title":"Cancer Sci"},{"key":"2026012203145573100_bib34","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.lungcan.2010.04.014","article-title":"The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias","volume":"71","author":"Minegishi","year":"2011","journal-title":"Lung Cancer"},{"key":"2026012203145573100_bib35","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s10147-019-01516-9","article-title":"Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study","volume":"24","author":"Fukuizumi","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"2026012203145573100_bib36","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00280-016-3040-8","article-title":"Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study","volume":"77","author":"Sekine","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026012203145573100_bib37","doi-asserted-by":"crossref","first-page":"2200380","DOI":"10.1183\/13993003.00380-2022","article-title":"Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial","volume":"60","author":"Otsubo","year":"2022","journal-title":"Eur Respir J"},{"key":"2026012203145573100_bib38","doi-asserted-by":"crossref","first-page":"20406223221108395","DOI":"10.1177\/20406223221108395","article-title":"Chemotherapy for patients with advanced lung cancer with interstitial lung disease: a prospective observational study","volume":"13","author":"Koda","year":"2022","journal-title":"Ther Adv Chronic Dis"},{"key":"2026012203145573100_bib39","doi-asserted-by":"crossref","first-page":"00184-02019","DOI":"10.1183\/23120541.00184-2019","article-title":"Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan","volume":"6","author":"Minegishi","year":"2020","journal-title":"ERJ Open Res"},{"key":"2026012203145573100_bib40","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1164\/rccm.201503-0562OC","article-title":"Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS","volume":"193","author":"Costabel","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203145573100_bib41","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1159\/000533312","article-title":"Acute exacerbation and proposed criteria for progressive pulmonary fibrosis in patients with fibrotic hypersensitivity pneumonitis and idiopathic pulmonary fibrosis","volume":"102","author":"Okuda","year":"2023","journal-title":"Respiration"},{"key":"2026012203145573100_bib42","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41584-021-00721-z","article-title":"Acute exacerbation of interstitial lung disease associated with rheumatic disease","volume":"18","author":"Luppi","year":"2022","journal-title":"Nat Rev Rheumatol"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/21\/4\/635\/66009705\/annalsats_21_4_635.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/21\/4\/635\/66009705\/annalsats_21_4_635.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:16:03Z","timestamp":1769069763000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/21\/4\/635\/8382032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,1]]},"published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202311-941oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,4,1]]},"assertion":[{"value":"2023-11-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}